Advancing Inflammatory Bowel Disease Treatment by Targeting the Innate Immune System and Precision Drug Delivery
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26020575 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Kat F Kiilerich und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, University of Southern Denmark, 5000 Odense, Denmark. Hauptthemen laut MEDLINE: Immunity, Innate, Inflammatory Bowel Diseases, Drug Delivery Systems. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, involves chronic inflammation of the gastrointestinal tract. Current immune-modulating therapies are insufficient for 30–50% of patients or cause significant side effects, emphasizing the need for new treatments. Targeting the innate immune system and enhancing drug delivery to inflamed gut regions are promising strategies. Neutrophils play a central role in IBD by releasing reactive oxygen species (ROS) and neutrophil extracellular traps (NETs) —DNA-based structures with cytotoxic proteins—that contribute to mucosal damage and inflammation. Recent studies linking ROS production, DNA repair, and NET formation have identified NETs as potential therapeutic targets, with preclinical models showing positive outcomes from NET inhibition. Innovative oral drug delivery systems designed to target gut inflammation directly—without systemic absorption—could improve treatment precision and reduce side effects. Advanced formulations utilize properties such as particle size, surface modifications, and ROS-triggered release to selectively target the distal ileum and colon. A dual strategy that combines a deeper understanding of IBD pathophysiology to identify inflammation-related therapeutic targets with advanced drug delivery systems may offer significant promise. For instance, pairing NET inhibition with ROS-responsive nanocarriers could enhance treatment efficacy, though further research is needed. This synergistic approach has the potential to greatly improve outcomes for IBD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Medicine, University of Southern Denmark, 5000 Odense, Denmark.
- Department of Health Science and Technology, The Faculty of Medicine, Aalborg University, 9220 Aalborg Ø, Denmark.
- Molecular Diagnostic and Clinical Research Unit, University Hospital of Southern Denmark, 6200 Aabenraa, Denmark.
- Department of Regional Health Research, University of Southern Denmark, 5000 Odense, Denmark.
- Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, 5000 Odense, Denmark.
- Danish Institute for Advanced Study, University of Southern Denmark, 5000 Odense, Denmark.
ORCID-Profile: Kat F Kiilerich, Behrooz Darbani, Anette Liljensøe, Tue B Bennike, René Holm, Jesper B Moeller, Vibeke Andersen
Zitieren
APA
Kiilerich, K. F., Andresen, T., Darbani, B., Gregersen, L. H. K., Liljensøe, A., Bennike, T. B., Holm, R., Moeller, J. B., & Andersen, V. (2025). Advancing Inflammatory Bowel Disease Treatment by Targeting the Innate Immune System and Precision Drug Delivery. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26020575
Vancouver
Kiilerich KF, Andresen T, Darbani B, Gregersen LHK, Liljensøe A, Bennike TB, et al. Advancing Inflammatory Bowel Disease Treatment by Targeting the Innate Immune System and Precision Drug Delivery. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26020575
BibTeX
@article{Kiilerich2025,
author = {Kiilerich, Kat F and Andresen, Trine and Darbani, Behrooz and Gregersen, Laura H K and Liljensøe, Anette and Bennike, Tue B and Holm, René and Moeller, Jesper B and Andersen, Vibeke},
title = {Advancing Inflammatory Bowel Disease Treatment by Targeting the Innate Immune System and Precision Drug Delivery},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26020575}
}
EUVIMED